Jiangsu Hengrui Pharmaceuticals Co Ltd is a pharmaceutical company engaged in the research, development, manufacturing, and sale of medicines. The company operates across three main business segments: oncology, anesthesiology, and ophthalmology, with a focus on anti-tumor drugs, surgical medications, and imaging intervention products. Its product portfolio includes monoclonal antibodies such as Camrelizumab (AiRuiKa) and Recaticimab (AiXinAn), small-molecule inhibitors like Pyrotinib (AiRuiNi) and Apatinib (AiTan), and metabolic therapies including Retagliptin (RuiZeTang) and Retagliptin Phosphate and Metformin Hydrochloride (RuiLinTang). The company serves patients with conditions including breast cancer, gastric cancer, hepatocellular carcinoma, non-small cell lung cancer, and type 2 diabetes. Founded in 1970, the company serves markets in China and internationally, including collaborations with organizations in Hong Kong and applications for approval in Europe.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Drug Manufacturers - General Homepage hengrui.com
Sector Healthcare IR page hengrui.com/investor
Tags
oncology, anesthesiology, ophthalmology, metabolic diseases, cardiovascular diseases, monoclonal antibodies, small molecule drugs, pd-1 inhibitors, egfr inhibitors, dpp-4 inhibitors, pcsk9 inhibitors, type 2 diabetes, Camrelizumab, AiRuiKa, Pyrotinib, AiRuiNi, Mecapegfilgrastim, AiDuo, Apatinib, AiTan, Retagliptin Phosphate and Metformin Hydrochloride, RuiLinTang, Recaticimab, AiXinAn, Retagliptin, RuiZeTang, Fuzuloparib, SHR-3167
Press page —

Metrics

Valuation  
Market cap HK$ 289.541B
Market cap (USD) $ 36.9B
P/E 34.00
PEG —
P/BV —
P/S —
P/OCF —
P/FCF —
Dividend yield 0.50%
Turnover / mcap 0.08%
Returns  
ROE 14.3%
ROI 12.5%
ROIC 12.5%
Profit margin 24.4%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock —
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score 61.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024
Revenue 31.629B 27.985B
Net profit 7.711B 6.337B

Figure FY 2025 FY 2024
Share price 63.93 —
P/E 53.73 —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Jiangsu Hengrui Pharmaceuticals Co Ltd (ticker 1276), listed in Hong Kong.

ETFs Holding Jiangsu Hengrui Pharmaceuticals Co Ltd

ETF Weight in ETF Shares Market value As of
OZEM 4.14% 380,200 $ 2.309M Nov 17, 2026
JSTC 0.03% 15,682 $ 97.86K Nov 17, 2026